VONJO Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving VONJO Growth

• Unique positioning in severe thrombocytopenic myelofibrosis with limited competition

VONJO (pacritinib) is the first and only FDA-approved therapy specifically indicated for adults with intermediate- or high-risk primary or secondary myelofibrosis (MF) and platelet counts < 50 × 10⁹/L, addressing a patient population with significant unmet need where other JAK inhibitors are often difficult to use because of worsening cytopenias. This differentiated label provides a competitive advantage in a niche but clinically important segment of the MF market and supports continued uptake among hematologists.

• Strong efficacy demonstrated in the Phase III PERSIST-2 trial

VONJO's approval was based on the Phase III PERSIST-2 study, the only randomized trial specifically designed for cytopenic MF patients. Among patients with platelet counts < 50 × 10⁹/L, 29% of those treated with pacritinib achieved ≥35% spleen volume reduction (SVR35) compared with 3% receiving best available therapy (BAT). Clinically meaningful symptom improvement was also observed, supporting its use in patients who historically had limited therapeutic options. These data continue to reinforce physician confidence and support prescribing growth.

• Expanding physician adoption through NCCN guideline recommendations

VONJO has been incorporated into the National Comprehensive Cancer Network (NCCN) Guidelines as a preferred treatment option for patients with severe thrombocytopenia and is also recommended in selected patients with platelet counts ≥50 × 10⁹/L following prior JAK inhibitor therapy. More recently, NCCN updates have also recognized pacritinib as a treatment option for myelofibrosis-associated anemia, potentially expanding its addressable patient population beyond its original FDA label. Guideline inclusion is expected to improve payer coverage and increase utilization in both academic and community oncology practices.

• Differentiated mechanism of action addressing multiple disease pathways

Unlike currently available JAK inhibitors, VONJO inhibits JAK2, IRAK1, and ACVR1 while largely sparing JAK1. ACVR1 inhibition may reduce hepcidin production and improve anemia, while IRAK1 inhibition may further suppress inflammatory signaling involved in MF pathogenesis. This differentiated pharmacologic profile provides potential advantages for patients with thrombocytopenia and anemia, supporting continued clinical interest and future label-expansion opportunities.

• Growing commercial adoption supported by launch performance

Commercial uptake has remained encouraging since launch. During 2022, more than 1,000 patients were commercially treated with VONJO, generating approximately US$54 million in net sales during the first nine months following launch. More recently, Sobi has reported stable demand with continued opportunities to expand utilization in both the approved < 50 × 10⁹/L population and the broader 50-100 × 10⁹/L platelet subgroup in line with NCCN recommendations.

• Further growth supported by confirmatory studies and moderate sales outlook

Continued development of the PACIFICA confirmatory trial is expected to support conversion from accelerated to traditional FDA approval while generating additional long-term efficacy and survival data. Successful completion could strengthen physician confidence and broaden reimbursement. Commercially, VONJO remains an orphan hematology product with steady growth potential. Based on publicly available company disclosures and consensus financial estimates (rather than market research reports), annual global sales are generally expected to reach approximately US$150-250 million over the next several years, driven by increased penetration in severe thrombocytopenic MF, expanded guideline adoption, and continued commercial execution.

VONJO Recent Developments

In May 2023, Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) today announced that it has entered into an agreement and plan of merger with CTI BioPharma Corp. (CTI) under which Sobi has agreed to acquire CTI, a biopharmaceutical company focused on blood related cancers and rare diseases, by means of a tender offer.

The acquisition complements and further strengthens Sobi’s leading haematology franchise by adding VONJO® (pacritinib), a novel oral kinase inhibitor that inhibits JAK2, IRAK1 and ACRV1, while sparing JAK1. VONJO obtained accelerated approval by the FDA in February 2022 for treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.

“VONJO Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of VONJO for approved indication like Myelofibrosis; as well as potential indication like Graft-versus-host disease and VEXAS syndrome in the 7MM. A detailed picture of VONJO’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the VONJO for approved and potential indications. The VONJO market report provides insights about VONJO’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current VONJO performance, future market assessments inclusive of the VONJO market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of VONJO sales forecasts, along with factors driving its market.

VONJO Drug Summary

VONJO (Pacritinib) is an oral kinase inhibitor with selective activity against JAK2, IRAK1, and ACVR1, approved for the treatment of adults with intermediate- or high-risk primary or secondary myelofibrosis who have severe thrombocytopenia (platelet count below 50 × 10⁹/L). VONJO is designed to control disease by inhibiting aberrant JAK2-mediated signaling while offering a treatment option for patients with profound thrombocytopenia, a population with limited therapeutic choices. Administered orally twice daily, VONJO has demonstrated clinically meaningful reductions in spleen volume and improvements in myelofibrosis-related symptoms in pivotal clinical trials, including the PERSIST and PACIFICA development programs, with a comparatively favorable profile regarding myelosuppression in severely thrombocytopenic patients. The most common adverse events include diarrhea, nausea, thrombocytopenia, anemia, and peripheral edema, and patients require monitoring for bleeding, cardiac events, and infections. Approved by the U.S. FDA in 2022, VONJO represents an important targeted therapy for myelofibrosis patients with severe thrombocytopenia, addressing a significant unmet need in this high-risk subgroup. The report provides VONJO’s sales, growth barriers and drivers, post usage and approvals in multiple indications. 

Scope of the VONJO Market Report

The report provides insights into:

• A comprehensive product overview including the VONJO MoA, description, dosage and administration, research and development activities in approved indications like Myelofibrosis; as well as potential indication like Graft-versus-host disease and VEXAS syndrome.
• Elaborated details on VONJO regulatory milestones and other development activities have been provided in VONJO market report.
• The report also highlights VONJO‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The VONJO market report also covers the patents information, generic entry and impact on cost cut.
• The VONJO market report contains current and forecasted VONJO sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The VONJO market report also features the SWOT analysis with analyst views for VONJO in approved and potential indications.

Methodology

The VONJO market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VONJO Analytical Perspective

• In-depth VONJO Market Assessment

This VONJO sales market forecast report provides a detailed market assessment of VONJO for approved indication like Myelofibrosis; as well as potential indication like Graft-versus-host disease and VEXAS syndrome in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted VONJO sales data uptil 2034.

• VONJO Clinical Assessment

The VONJO market report provides the clinical trials information of VONJO for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

VONJO Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

VONJO Market Potential & Revenue Forecast

• Projected market size for the VONJO and its key indications
• Estimated VONJO sales potential (VONJO peak sales forecasts)
• VONJO Pricing strategies and reimbursement landscape

VONJO Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• VONJO Market positioning compared to existing treatments
• VONJO Strengths & weaknesses relative to competitors

VONJO Regulatory & Commercial Milestones

• VONJO Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

VONJO Clinical Differentiation

• VONJO Efficacy & safety advantages over existing drugs
• VONJO Unique selling points  

VONJO Market Report Highlights

• In the coming years, the VONJO market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The VONJO companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VONJO’s dominance.
• Other emerging products for Myelofibrosis; as well as potential indication like Graft-versus-host disease and VEXAS syndrome are expected to give tough market competition to VONJO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VONJO in approved and potential indications.
• Analyse VONJO cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted VONJO sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of VONJO in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of VONJO? How strong is VONJO’s clinical and commercial performance?
• What is VONJO’s clinical trial status in each individual indications such as Myelofibrosis; as well as potential indication like Graft-versus-host disease and VEXAS syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VONJO Manufacturers?
• What are the key designations that have been granted to VONJO for approved and potential indications? How are they going to impact VONJO’s penetration in various geographies?
• What is the current and forecasted VONJO market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of VONJO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to VONJO for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is VONJO? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.